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ABSTRACT
Transcription and pre-mRNA splicing are the key
nuclear processes in eukaryotic gene expression,
and identification of factors common to both
processes has suggested that they are functionally
coordinated. p100 protein has been shown to
function as a transcriptional co-activator for several
transcription factors. p100 consists of staphylococ-
cal nuclease (SN)-like and Tudor-SN (TSN) domains
of which the SN-like domains have been shown to
function in transcription, but the function of TSN
domain has remained elusive. Here we identified
interaction between p100 and small nuclear ribonu-
cleoproteins (snRNP) that function in pre-mRNA
splicing. The TSN domain of p100 specifically
interacts with components of the U5 snRNP, but
also with the other spliceosomal snRNPs. In vitro
splicing assays revealed that the purified p100, and
specifically the TSN domain of p100, accelerates the
kinetics of the spliceosome assembly, particularly
the formation of complex A, and the transition from
complex A to B. Consistently, the p100 protein, as
well as the separated TSN domain, enhanced the
kinetics of the first step of splicing in an in vitro
splicing assay in dose-dependent manner. Thus our
results suggest that p100 protein is a novel dual
function regulator of gene expression that partici-
pates via distinct domains in both transcription
and splicing.
INTRODUCTION
Transcription and pre-mRNA splicing are the two key
nuclear steps regulating gene expression in eukaryotes.
Both transcription and splicing are highly ordered
processes involving intricate protein–protein interactions.
Transcription is regulated by protein complex composed
of transcription factors, basal transcriptional machinery
and a group of co-activators (1), while pre-mRNA splicing
is carried out by spliceosome that consists of ﬁve
conserved small nuclear ribonucleoprotein particles
(snRNPs) U1, U2, U5, base-paired U4/U6 and a large
number of less precisely deﬁned non-snRNP proteins (2).
Accumulating evidence supports the concept that
transcription and splicing are coordinated (3–5). The key
factor linking these processes is the C-terminal domain
(CTD) of pol II large subunit which plays essential role
both in transcription and RNA processing (6,7).
Additionally, CTD associates with general RNA proces-
sing machineries, functioning in mRNA capping, pre-
mRNA splicing, polyadenylation and alternative splicing
(8–10). However, recent evidence supports the idea that
CTD is required for eﬃcient co-transcriptional editing of
some pre-mRNA, but is not required for eﬃcient splicing
of the pre-mRNA (11). Thus, the CTD is most likely a
coordinator, rather than a simple enhancer of RNA
processing. Additional evidence supporting the coupling
between transcription and polyadenylation is emerging
from recent proteomic analyses of the human spliceosome
which revealed that at least 30 spliceosomal proteins are
also participating in other gene expression steps besides
splicing (12–14). For example, transcription cofactor such
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SKIP (Ski-binding protein) (17) have also been identiﬁed
in the spliceosome. These results imply that gene expres-
sion machineries are extensively coupled via protein–
protein interactions. However, although the evidence of
CTD recruitment of mRNA processing factors is well
documented, the interactions between CTD and other
proteins that link transcription and RNA processing
have been poorly characterized. Hence, identiﬁcation of
functional protein complexes and the shared protein
components between them is an essential step in under-
standing the physiological mechanisms that couple
transcription and RNA processing.
p100 protein was ﬁrst identiﬁed as a co-activator of
EBNA2 (Epstein–Barr virus nuclear protein 2) (18), and
subsequently discovered as co-regulator of pim-1 (19), and
STAT6 transcription factor in IL-4 mediated gene
regulation (20,21). p100 functions also as a co-activator
of STAT5 in prolactin (PRL) signaling (22), and in
mammary epithelial cells p100 protein levels increase in
response to PRL during lactation and correlate with
induction of b-casein gene expression (23). In addition,
p100 has been linked to the pathogenesis of autosomal-
dominant polycystic kidney disease (ADPKD) (24), and
identiﬁed in the RISC (RNA-induced silencing complex)
(25). These studies suggest that p100 protein participates
in several biological responses and that the protein may
play distinct roles in various cellular events.
p100 protein consists of four similar domains with
homology to the staphylococcal nucleases (SN), followed
by a C-terminal Tudor-SN (TSN) domain (26). The SN-
like domains of p100 have been implicated in protein
interactions, and the SN-like domains of p100 protein
recruit CBP and RNA pol II to STAT6 and facilitate the
formation of STAT6 enhanceosome (20). The function of
p100 TSN domain has remained elusive, but the Tudor
domain is 30% homologous to SMN (survival of motor
neuron protein) Tudor domain, which functions in the
assembly of snRNP complexes and pre-mRNA splicing
process (27,28; Figure 6).
In this report, we demonstrate a novel function for p100
protein as an interaction partner for spliceosomal
snRNPs. First, we used an in vitro pull-down assay to
demonstrate that TSN domain of p100 protein associates
with a subset of U5 snRNP core proteins, and is capable
of precipitating all snRNAs. We next showed that
exogenously added p100 protein can kinetically enhance
both the in vitro spliceosome complex formation and the
ﬁrst step of pre-mRNA splicing. Thus our results suggest
that human p100 protein is a novel dual function regulator
of both gene transcription and pre-mRNA splicing.
MATERIALS AND METHODS
Plasmids andcells
HeLa cells and COS-7 cells were cultured as described
previously (21). The HeLa-p100-Flag stable cell lines were
cloned as described previously(21). Plasmid encoding
AdML pre-mRNA was kindly provided by Dr R. Reed
(14). The pSG5 vector expression plasmids containing
full-length p100 tagged with Flag sequence, GST-p100-
TSN and GST-p100-SN were generated as previously
described (21). GST-SMN-Tudor was generated by
cloning PCR products corresponding to amino acids
92–156 of SMN and inserted into pGEXT-4T-1 with
EcoRI and NotI. pBluescript plasmids containing diﬀer-
ent domains of U5-220, which could be used for in vitro
translation, were constructed by cloning PCR products
corresponding to amino acids 1–209 (domain 1), 303–668
(domain 2), 673–907 (domain 3), 914–1170 (domain 4),
1167–1698 (domain 5), 1697–2121 (domain 7), 2040–2332
(domain 7). All PCR products were sequenced.
GST pull-down assays
GST pull-down experiments were performed as described
previously(21). GST fusion proteins were bound on
glutathione-Sepharose 4B beads (Amersham Biosciences,
Little Chalfont, Buckinghamshire, UK) and incubated
with HeLa cell nuclear lysates or in vitro-translated
35S-labeled diﬀerent domains of U5-220 in binding
buﬀer (12.5mM HEPES pH 7.4, 0.1mM EDTA, 0.05%
NP-40, 1mM DTT, 2mg/ml aprotinin, 0.5% bovine
serum albumin). The beads were washed with buﬀer
containing 300mM NaCl, and then separated by SDS–
PAGE and visualized by silver staining, Coomassie blue
staining or autoradiography.
Mass spectrometry
For mass spectrometric analysis, in order to avoid the
contamination of GST fusion protein, the precipitated
proteins were dissociated from bead-bound GST-p100-
TSN fusion protein by incubating in the elution buﬀer
containing 2M NaCl, and then concentrated and desalted
with Microcon column (cut-oﬀ 30kDa, Millipore
Corporation, Bedford, MA, USA) by centrifugation at
13000r.p.m. for 30min. The precipitated proteins were
separated by SDS–PAGE and visualized by silver staining
or Coomassie blue staining. The bands corresponding to
the 220-kDa, 200-kDa and 116-kDa proteins were cut out
from Coomassie blue-stained gel and subjected to trypsin
digestion as described previously (21). The molecular
masses of the peptide mixtures were determined by
matrix-assisted laser desorption ionization time-of-ﬂight
(MALDI-TOF) mass spectrometry. The molecular masses
of the tryptic peptides of the 220kDa, 200kDa and
116kDa proteins were used to search the OWL protein
sequence database for candidate proteins using the
ProFound program.
Immunoprecipitation
The nuclear extracts of p100 stable HeLa cells were
immunoprecipitated with anti-Prp8 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-Flag M2
agarose (Sigma, St Louis, MO, USA), anti-IgG (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), or anti-
TMG (trimethyl-guanosine) monoclonal antibody cross-
linked to agarose beads (Calbiochem, San Diego, USA).
The bound proteins were subjected to SDS–-PAGE and
blotted with anti-Prp8 antibody, anti-Flag M2 antibody
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against TSN domain of p100 protein).
Protein purification
COS-7 cells were transfected with pSG5-p100-Flag as
previously described (21). Transfected COS-7 cells were
suspended in Nonidet P-40 lysis buﬀer (50mM Tris–HCl,
pH 7.6, 300mM NaCl, 0.1mM EDTA, 0.5% Nonidet
P-40, 20% glycerol, 0.1mM sodium orthovanadate, 1mM
sodium butyrate). The total cell lysates were incubated
with mouse monoclonal anti-Flag M2 agarose at 48C for
2h with head-over-tail rotation. After washing with
stringent buﬀer (containing 700mM NaCl), the puriﬁed
p100 proteins (P-p100) were eluted from the agarose with
Flag peptide (100mg/ml) (Sigma, St Louis, MO, USA),
and concentrated with Microcon column. The purity of
P-p100 was conﬁrmed by SDS–PAGE and silver staining.
GST-p100-TSN and GST-p100-SN fusion proteins
were bound on glutathione- Sepharose 4B beads. After
washing, the p100-SN or p100-TSN proteins were cleaved
from the GST with thrombin (Sigma, St Louis, MO,
USA), and concentrated with Microcon column. The GST
proteins were detached from the beads with reduced
glutathione (10mM) (Sigma, St Louis, MO, USA). The
purity of GST, p100-SN and p100-TSN was detected by
SDS–PAGE and silver staining.
In vitro splicing assays andspliceosome analysis
Capped adenovirus splicing substrates that were uni-
formly labeled with
32P-UTP were produced by in vitro
transcription with T7 RNA polymerase (Promega,
Madison, WI, USA) using plasmid pAdML linearized
with HindIII as template (14). The labeled RNAs were
puriﬁed in denaturing polyacrylamide gel before use. The
splicing reactions, containing 40% (v/v) HeLa nuclear
extracts, 2mM MgCl2, 10mM DTT, 20mM creatine
phosphate, 2mM ATP, were supplemented with various
recombinant proteins and pre-incubated at 308C for
10min, followed by the addition of 10000c.p.m. pre-
mRNA. After incubating at 308C for diﬀerent time points,
the reactions were stopped by addition of 150ml PK buﬀer
(20mM Tris, 10mM EDTA, 300mM NaCl, 4.5mg/ml
proteinase K, 0.5% SDS and 0.14mg/ml glycogen), and
the incubation was continued for 30min at the same
temperature (29). Reactions were extracted with phenol
and the RNA was recovered by ethanol precipitation.
Subsequently, RNA pellets were resolved in gel loading
buﬀer containing 7.5M urea, denatured at 958C for 5min,
chilled on ice before loading on an 8% denatured PAGE
with 7M urea. The gels were visualized by phosphoimager
(Fuji FLA-5010).
Native gel analysis on 4% acrylamide was performed as
described before (30) and visualized by phosphorimager
and autoradiography. Heparin (1mg/ml ﬁnal con-
centration) was added to the splicing reactions prior to
loading.
RNA extractions and northernblotting
The nuclear extracts of HeLa cells that displayed stable
expression of p100 were immunoprecipitated with
anti-IgG or anti-TMG monoclonal antibody cross-linked
to agarose beads. After washing, the beads were incubated
with 300ml PK buﬀer at 658C for 60min. After extraction
with phenol/chloroform, RNA was precipitated in etha-
nol. The bead-bound GST fusion proteins were incubated
with HeLa cell nuclear lysates (100mM or 300mM NaCl),
the precipitated RNA was extracted as described above.
The RNA was separated on denatured 6% PAGE
gels, transferred to a nylon ﬁlter with semi-dry blotter
(Owl Scientiﬁc, Woburn, MA, USA) in 0.5X Tris–EDTA
buﬀer using a constant 3mA/cm
2 current for 1.5–2h,
followed by cross-linking with stratalinker (Stratagene,
La Jolla, CA, USA).
Hybridization condition for snRNA blots has been
described previously (31). Radiolabeled probes of U1
snRNA, U2 snRNA, U4 snRNA, U5 snRNA and U6
snRNA, were made by in vitro transcription of the
linearized snRNA plasmids. U7 and 7SK probes were
made by PCR and labeled with
32P-UTP as described
before (31).
RESULTS
Identification of U5snRNP specific proteins as interacting
proteins ofp100
Human p100 protein is composed of four repeats of
SN-like domains followed by a C-terminal TSN domain
(Figure 1A). The SN consists of two subdomains. The ﬁrst
subdomain belongs to the large oligonucleotide/
Figure 1. Interaction between p100 protein and U5 snRNP speciﬁc
proteins. (A) The schematic structure of p100 protein (B) Pulldown of
U5 speciﬁc proteins using TSN domain of p100. Aliquots of nuclear
lysates from HeLa cells were incubated with either GST alone or with
GST-p100-TSN. The bound proteins were subjected to SDS–PAGE
and visualized by Coomassie blue or silver staining and identiﬁed
by mass spectrometry. (C) The loading control of GST and GST-
p100-TSN proteins.
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the second subdomain consists of two independently
folded a-helices. The TSN domain is a hybrid SN
domain, in which the OB-domain is divided by a
domain found in Drosophila melanogaster Tudor protein.
According to the crystal structure of p100 TSN domain
(Shaw,N. et al., submitted for publication), the Tudor
domain is ﬂanked by two segments of SN, thus we refer it
as TSN domain instead, to diﬀerentiate it from the bona
ﬁde Tudor domains.
In order to identify p100 TSN domain interacting
proteins, a pull-down assay with GST-p100-TSN fusion
protein was carried out. Equal amounts of GST or GST-
p100-TSN fusion proteins were bound to glutathione
coupled beads and incubated with nuclear extracts of
HeLa cells. The precipitated proteins were prepared as
described above. Due to the relatively large cut-oﬀ
(30kDa) of the Microcon columns and the high salt
concentration used in the elution, many of the larger
complexes were expected to be dissociated, and the smaller
protein components of such complexes were most likely
lost during the centrifugation step. As shown in Figure 1B,
several proteins were found to speciﬁcally interact with
TSN domain of p100 protein. The bands corresponding to
220kDa, 200kDa and 116kDa proteins were recovered
and subjected to in-gel trypsin digestion. The molecular
masses of the digested peptides were analyzed by MALDI-
TOF mass spectrometry. The program ProFound was
used to compare the mass maps obtained against
theoretical tryptic peptide mass maps in the OWL protein
sequence database. The comparison resulted in the
identiﬁcation of a group of U5 snRNP speciﬁc proteins:
p220 is human U5-220 (splicing factor Prp8 in yeast), p200
is human U5-200 (DEXH box RNA helicase, Brr2
in yeast), p116 is human U5-116 (a putative GTPase
homologous to the ribosomal elongation factor EF-2,
Snu114 in yeast).
p100 proteincan interact withsnRNPs complexes in vivo
and in vitro
To analyze the possible in vivo association of p100 protein
and U5-220, co-immunoprecipitation experiments were
carried out in HeLa cells which stably express Flag-tagged
human p100 protein (HeLa-p100). The nuclear extracts
of these cells were immunoprecipitated with anti-Flag
agarose, or rabbit anti-IgG antibody as a control. The
precipitated proteins were separated by SDS–PAGE and
blotted with anti-Flag or anti-Prp8 antibodies. As shown
in Figure 2A, anti-Flag antibodies, but not IgG control,
precipitated the endogenous U5-220.
In vivo complex formation was conﬁrmed by a
reciprocal experiment in which the nuclear extracts of
HeLa-p100 cells were immunoprecipitated with anti-Prp8
antibody, or rabbit anti-IgG antibody as a control, and
precipitated proteins were detected by blotting with anti-
Prp8 antibody or anti-Flag antibody. As shown in
Figure 2B, U5-220 but not IgG control, precipitated the
p100-Flag. These results demonstrate that p100 protein
and U5-220 are associated, either directly or indirectly,
in vivo. We did not have access to antibodies speciﬁc
to Brr2 or Snu114, and therefore, we were not able to
conﬁrm the in vivo association of p100 protein and the
other two U5 snRNP speciﬁc proteins identiﬁed in our
mass spectrometry analysis.
In order to further verify the interaction of p100 protein
and U5-220, GST pull-down assay was performed by
incubating the in vitro-translated diﬀerent domains of
U5-220 with beads-bound GST-p100-TSN fusion protein,
or GST as control. As shown in Figure 2C, domain 2
(aa 303–668) of U5-220 interacted with TSN domain
Figure 2. p100 protein associates with U5-220 in vivo.( A) The nuclear extracts of HeLa-p100 cells were immunoprecipitated with anti-Flag agarose
or anti-IgG as control. The bound proteins were subjected to SDS–PAGE and blotted with anti-Prp8 antibody (upper panel) or anti-Flag antibody
(lower panel). (B) Alternately, the nuclear extract of HeLa-p100 cells were immunoprecipitated with anti-Prp8 or anti-IgG as control. The bound
proteins were subjected to SDS–PAGE and blotted with anti-Flag (upper panel) or anti-Prp8 antibody (lower panel). The input is 15% of the lysate
for IP reaction. (C) TSN domain of p100 protein interacts with U5-220 in vitro. Diﬀerent domains of U5-220 were
35S-labeled by in vitro translation
and incubated with beads loaded with GST-p100-TSN or GST. The bound proteins were subjected to 8% SDS–PAGE and visualized by
autoradiography. Twenty percent of the in vitro-translated protein was included as a control. The domain 2 has similar molecular weight as the
GST-p100-TSN; due to large amount of GST-p100-TSN protein present in the lane, the migration of the domain 2 is somewhat aberrant.
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domains of U5-220 did not associate with either GST
alone, or GST-p100-TSN fusion protein. These results
demonstrated that p100 protein interacts with U5-220
protein both in vivo and in vitro.
To ask if the other snRNPs are the targets of the TSN
domain of p100, GST pull-down assays were performed
with GST-p100-TSN and HeLa nuclear lysates. After
pulldown, the beads were washed in the buﬀer containing
300mM NaCl, followed by both western blotting
analysis (with anti-Prp8) and northern blot analysis
using snRNA-probes speciﬁc to the major U2-dependent
spliceosome (U1, U2, U4, U5 and U6 snRNAs), U7
snRNA functioning in histone mRNA processing, or 7SK
snRNA, a component of the transcription elongation
factor P-TEFb.
Consistent with the original pulldown and proteomic
analysis, the western blotting results showed that the
GST-p100-TSN precipitated U5-220, while GST-p100-SN
or GST protein alone did not (Figure 3A). Additionally,
northern analysis of the pull-down reactions using
spliceosomal snRNA-speciﬁc probes and U7-speciﬁc
probe revealed, similarly to the control SMN pull-down,
an eﬃcient pull-down with the GST-p100-TSN fusion
protein (Figure 3C). In contrast, no interaction was
observed with the 7SK, which is another nuclear
snRNP. This suggests that the common features of
spliceosomal U-snRNPs and U7 snRNP, Sm-proteins
and trimethylated cap structure may be recognized by
p100-TSN domain, because both features are missing
from 7SK RNP. U6 snRNP lacks these features as well,
but its precipitation is promoted by base-pairing with U4.
To further validate the association of p100 protein with
snRNPs, the nuclear extracts of HeLa-p100 cells were
immunoprecipitated with anti-trimethylguanosine (TMG)
cap antibody (32), or rabbit anti-IgG antibody as control
using the same salt concentration as above (300mM
NaCl). The TMG-cap is present in U1, U2, U4 and U5
snRNAs (33), while the U6 snRNA contains a mono-
methyl cap instead, but is base-paired in vivo with the
U4 snRNA which contains a TMG-cap. Northern
analysis revealed that U1, U2, U4, U5 and U6 snRNAs
were all present in the anti-TMG immunoprecipitates,
but not in the anti-IgG control sample (Figure 3E).
Additionally, western blot analysis of the anti-TMG-cap
immunoprecipitates indicated that the p100 protein was
co-immunoprecipitated with anti-TMG-cap antibody, but
not with the anti-IgG antibody (Figure 3D). The eﬃcient
co-immunoprecipitation of p100 with TMG antibody
indicates that the TMG-cap structure itself is not a
target for p100. Together, these results suggest that the
p100 protein can interact with both U5-speciﬁc proteins
and with Sm-proteins.
p100protein accelerates thespliceosome assembly and
pre-mRNA splicing processin vitro
In order to investigate the functional signiﬁcance of p100-
snRNP interaction, we tested the eﬀect of the p100 on
in vitro splicing using splicing substrate (pre-mRNA)
derived from the adenovirus major late transcription unit
(AdML). Splicing reactions were either pre-incubated with
puriﬁed p100 protein or mock-treated, followed by the
addition of radiolabeled splicing substrate and subsequent
time-course analysis of the splicing reactions. The results
in Figure 4A show that the appearance of the ligated
mRNA and exon-lariat intermediate is faster and respond
in a dose-dependent manner (lanes 6–8, 10–12) as
compared to the reactions containing no exogenously
Figure 3. p100 protein associates with snRNP via TSN domain. (A) TSN domain of p100 protein interacts with a complex containing U5-220.
Nuclear lysate of HeLa cells were incubated with either GST alone, GST-p100-SN or GST-p100-TSN fusion proteins. The bound proteins were
resolved in SDS–PAGE and immunoblotted with anti-Prp8 antibody. The input is 10% of lysate. (B) The precipitated RNAs were analyzed by
northern blotting with U1, U2, U4, U5 and U6 snRNA probes, and then visualized by autoradiography. The positions of diﬀerent snRNAs are
indicated on the left. The input is 5% of extracted snRNA. (C) In a parallel experiment, the GST-p100-TSN and GST-SMN-Tudor (as positive
control) protein precipitated RNAs were analyzed by northern blotting with both U2-spliceosome and non-spliceosome (U7 and 7SK) snRNA
probes. The positions of diﬀerent snRNAs are indicated on the left. The input is 5% of extracted snRNA. (D) p100 protein is precipitated with anti-
TMG antibody in vivo. The nuclear extracts of HeLa-p100 cells were immunoprecipitated with anti-TMG antibody or anti-IgG as control. The
immunoprecipitates were separated by SDS–PAGE, immunoblotted with anti-p100 antibody. The input is 10% of lysate. (E) The precipitated RNAs
were analyzed as in panel B. The input is 5% of extracted snRNA.
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detectable signal from ligated mRNA and exon-lariat
intermediate were consistently observed at earlier time
point in splicing reactions containing p100. For example,
ligated mRNA appeared at 15min time point with 6-ng/ml
p100 protein (lane 10), and at 30min with 3-ng/ml p100
protein (lane 7), while it was hardly detectable at 30min in
the control (lane 3). Similar trend is seen with ligated
exons, which have reached their maximal intensity already
at 45min time point while the control reaction has not
(lanes 8 and 12 compare with lane 4). Signiﬁcantly, there
were no major diﬀerences in the levels of splicing
intermediates and products at the terminal 60-min time
point (lanes 5, 9 and 13) or after (data not shown),
suggesting that the added p100 does not increase the
overall level of in vitro splicing, but rather accelerates the
kinetics of the splicing reaction. As the second step is
not markedly inﬂuenced, that is, the amount of excised
intron was quantitatively similar in the splicing reactions
with or without addition of p100 protein (compare lanes 4,
8 and 12, lanes 5, 9 and 13), the results suggest that either
ﬁrst step, or the assembly steps prior to catalysis were
aﬀected. Control reactions with added BSA did not show
any stimulatory eﬀect on splicing, thus ruling out possible
eﬀects of overall protein concentration (data not shown).
To examine the possibility that the assembly steps prior
to the catalysis were aﬀected by p100, we analyzed the
formation of pre-spliceosomal complex A, fully assembled
spliceosomal complex B, and the catalytically active late
spliceosomal complex C using native gel electrophoresis
with AdML substrate. Figure 4B shows a time-course
analysis ofspliceosomal complexes usingdiﬀerentamounts
of p100 protein. The reactions were either kept on ice (0-
min time point), or incubated at 308C up to 60min prior to
gel analysis. In the control reaction (Figure 4B, lanes 1–5)
the non-speciﬁc complex H is ﬁrst detected at 0min time
point, complex A at 5min time point and the later B and C
complexes after 30min of incubation. In the presence of
p100 protein, we reproducibly observed relatively strong
complex A formation in reactions on ice (lanes 1, 6 and 11)
Figure 4. Eﬀect of p100 protein on the spliceosome assembly and splicing activity. In vitro splicing or spliceosome complex assembly reactions were
carried out with AdML splicing substrate in condition indicated above each lane. (A) The kinetics of the splicing reaction following the addition of
puriﬁed p100 protein. HeLa cell nuclear extracts were ﬁrst incubated for 20min on ice in the presence protein p100 storage buﬀer (lanes 2–5), or
diﬀerent concentrations (3ng/ml, 6ng/ml) of p100 protein (lanes 6–13), followed by an addition of ATP and creatine phosphate and a further
incubation at 308C for 10min. Subsequently, a-
32P-labeled AdML pre-mRNA was added, and the incubation continued at 308C for the time
indicated above each lane. RNA products were separated by electrophoresis in denaturing PAGE gels, and visualized by autoradiography. Splicing
intermediates and products are indicated on the left. (B) The eﬀect of p100 protein on spliceosomal complex formation in vitro. Native gel analysis of
spliceosome complexes formation in a mock-treated splicing reaction (lanes 1–5), or reactions pre-incubated with increasing concentrations (3ng/ml,
6ng/ml) of puriﬁed p100 protein (lanes 6–15). The gel was visualized by autoradiography. The bands corresponding to the H, A, B and C complexes
as well as the gel origin are indicated on the right. (C) Quantitative analysis of spliceosome formation. Native gels were quantiﬁed by phosphoimager
and normalized by setting the highest A complex value observed within each time series to 1.0.
4490 Nucleic Acids Research, 2007, Vol. 35, No. 13in a p100 protein dose-dependent manner. Additionally, in
those reactions the complex A band has reached its
maximal intensity already at 5min time point.
Furthermore, the kinetic appearance of B and C complexes
was also accelerated. The complex B could be detected
already at 5min time point in the reaction with 6-ng/ml
p100 protein (lane 12), and at 10min (lane 8) with 3-ng/ml
p100 protein, while at 30min (lane 4) in the control
reaction. Finally, there appears to be a faster turnover of
the splicing reaction particularly with the higher concen-
tration of the p100 as the level of complexes detected in the
native gel drops signiﬁcantly after 60min of incubation
(compare lanes 5, 10 and 15). Furthermore, the stimulation
of the complex formation appears to be dose-dependent as
the complex formation is faster in the reaction containing a
large amount of the p100 protein (compare reactions 6–10
and 11–15), which is consistent with the results observed in
splicing reactions (Figure 4A). To validate this point
further, we determined the intensities of A and
B complex from Figure 4B using a phosphoimager and
normalized each set by setting the highest value of complex
Ato 1. Asshown in Figure 4C, theaddition of p100 protein
accelerated the kinetics of complex A and B formation, the
transition of complex A to B (at 30min in control, 10min
with 3ng/ml and 5min with 6ng/ml p100 protein), and also
the decay at later time points.
To rule out possible stimulatory eﬀects of increased
protein concentration, similar native gel analyses were
carried out using equivalent amounts of control proteins,
such as GST (Figure 5) and BSA, neither of which changed
the kinetics of the complex formation (data not shown).
TSN domainof p100protein participates in the
pre-mRNA processing
To identify the domains of p100 protein responsible
for the observed stimulation of splicing kinetics we
performed in vitro splicing and spliceosome complex
analysis using the separated TSN and the SN domains
of the p100 protein. As shown in Figure 5A, addition of
the recombinant TSN domain resulted in clear accumula-
tion of ﬁnal product and lariat intermediate of RNA
already after 30min reaction (lanes 9 and 10, 12 and 13).
Figure 5. Eﬀect of p100 TSN domain on the spliceosome assembly and splicing activity. Nuclear extract pre-treatment and the splicing reactions were
done essentially as in Figure 4. (A) The kinetics of the AdML in vitro splicing in the presence of p100 storage buﬀer (lanes 2–4), 3ng/ml of GST (lanes
5–7), 3ng/ml p100-TSN (lanes 8–10), 6ng/ml p100-TSN (lanes 11–13) or 3ng/ml of p100-SN protein (lanes 14 and 15). Splicing intermediates and
products are indicated on the left. (B) Native gel analysis of spliceosome complexes. The nuclear extracts were mock-treated (lanes 1–5), or pre-
incubated with 3ng/ml of GST (lanes 6–10), p100-TSN (lanes 11–15) or p100-SN (lanes 16–20), respectively. The bands corresponding to the H, A, B
and C complexes as well as the gel origin are indicated on the right. (C) Quantitative analysis of spliceosome formation similarly as in Figure 4C.
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(in lanes 9 and 12, respectively) more intense than the
corresponding bands in lanes 3 and 6. The GST control
(lanes 5–7) did not display any diﬀerences compared to the
reaction without any additional protein (lanes 2–4).
Additionally, the isolated TSN-domain displays similar
dose-dependent stimulation of the splicing kinetics as the
full-length p100 protein (compare lanes 8–10 and 11–13).
At 30min time point (lanes 3, 6, 9 and 12), the amount
of ligated mRNA, especially the exon-lariat intermediates
were increased with the addition of TSN protein.
Surprisingly, the addition of recombinant SN domain of
p100 protein led to a total block of the splicing reaction
(lanes 14 and 15). Taken together, the splicing analysis
indicates that the TSN domain alone is suﬃcient to
accelerate the kinetics of the splicing reaction.
These results were conﬁrmed with the native gel
analysis. Consistent with the splicing result, the native
gel analysis demonstrated that TSN domain alone has a
similar function in splicing as the full-length p100 protein,
that is, it accelerated the kinetics of the spliceosomal
complex formation (Figure 5B lanes 11–15, Figure 5C),
while the GST control had no eﬀect on the pattern of
spliceosome assembly (Figure 5B, lanes 6–10). In
particular, in reactions containing 6-ng/ml GST-TSN
domain the A-complex reached it’s maximal intensity
after 5min incubation (Figure 5B, lane 12; 5C bottom
panel) while in control reactions, the maximal intensity
appeared after 30min incubation (Figure 5B, lanes 4 and
9; Figure 5C, top and middle panels). In contrast, addition
of the recombinant SN domain blocked the formation of
all the speciﬁc complexes, leading to a formation of an
unknown complex with an intermediate mobility between
H and A complexes (lanes 16–20). This result is consistent
with the observation above (Figure 5A), which indicated
that addition of the SN-domain alone caused a complete
inhibition of splicing, but at present we do not know
if it has any biological signiﬁcance.
DISCUSSION
The p100 protein is an evolutionarily conserved protein
present in the genomes of various eukaryotes from fungi
to vertebrates (for example, in Histoplasma capsulatum,
Saccharomyces pombe, Mus musculus, Bos taurus and
humans) (34,35). Human p100 protein is composed of
four repeats of SN-like domains and a TSN domain
(Figure 1A). The SN-domains consist of two subdomains
of which the ﬁrst subdomain belongs to the large OB-fold
superfamily, and the second subdomain consists of two
independently folded-helices (26). The TSN domain of
p100 is a hybrid of SN-like domain and a domain that is
found in multiple copies in the Drosophila melanogaster
Tudor protein.
We have previously shown that the SN domains of
human p100 recruit STAT6 and CBP to RNA pol II,
resulting in enhanced STAT6-mediated transcriptional
activation (20,21). Here we provide evidence that the TSN
domain of p100 protein is associated with U5 snRNP
via speciﬁc interactions with U5-220 both in vivo and
in vitro. Under high salt (700mM NaCl) concentrations
we detected association with the U5 snRNP speciﬁc
proteins including U5-220, U5-200 and U5-116, which is
consistent with previous reports showing that these
proteins form a stable, RNA-free subcomplex (36–39).
Additionally, under moderate salt concentrations we
observed interactions with U1, U2, U4, U5, U6 and U7
snRNPs, but not with 7SK snRNP. The appearance of
U7, but not 7SK in p100-TSN precipitation indicates
that p100 protein is likely to interact with snRNP via
recognition of TMG-cap or Sm-protein both of which are
present in spliceosomal snRNPs and in U7 snRNP. The
eﬃcient co-immunoprecipitation of p100 along with
the spliceosomal snRNPs using TMG-cap-speciﬁc anti-
body, argues that TMG-cap may not be the recognition
structure of p100, and suggests two modes for the
interaction of p100 and snRNPs, one is via the recruitment
of U5 snRNP, the other one is via the association of
Sm-protein. Finally, we provide evidence that addition of
p100 protein or the TSN-domain to an in vitro splicing
reaction accelerates the kinetics of splicing intermediate
and product formation by enhancing the complex A
formation and the transition from A to B complex
Comparison of the Tudor-domains of p100, splicing
factor SMNrp/SPF30 and SMN demonstrates sequence
similarity (Figure 6) between the Tudor domains. This is
further supported by our recent structural analysis of the
isolated TSN-domain of p100 using X-ray crystallography
(Shaw,N. et al., submitted for publication) demonstrating
that the TSN domain has a hydrophobic core, composed
of aromatic residues F715, Y721, Y738 and Y741, which is
highly similar to the Tudor domain of SMN. The
hydrophobic core mediates interactions between SMN
and the Sm-proteins, by binding with the dimethylarginine
modiﬁcations of the Sm-proteins (28,40,41). Consistent
with this hypothesis, mutations of the conserved tyrosine
residues (Y738A, Y741A) of the aromatic cage (Shaw,N.
et al., submitted for publication) abolished the interac-
tions between TSN domain and snRNAs.
The association of p100 protein and snRNPs resemble
the previous reports of SMNrp/SPF30 which interacts
with the U4/U6-90kDa protein present in tri-snRNP.
Similarly to our study, all snRNPs are co-immunopreci-
pitated with SMNrp/SPF30 antibodies, and conversely the
SMNrp/SPF30 is present in anti-TMG IP (42,43).
Interestingly, SMNrp/SPF30 has been shown to be
essential for the recruitment of the tri-snRNP to the
spliceosome (42,43), indicating that it functions during the
same spliceosome assembly step as p100 protein. It is
possible that the p100 utilizes similar interaction mechan-
isms as the SMNrp/SPF30 during the spliceosome
assembly, although the speciﬁc molecular interactions
are most likely diﬀerent.
We investigated the functional signiﬁcance of the p100:
snRNP interaction using an in vitro splicing and spliceo-
some complex-formation assays using a generic splicing
substrate (AdML), and found that p100 accelerated the
kinetics of the mature spliceosome formation before the
ﬁrst catalysis. Addition of either a puriﬁed full-length p100
protein or the plain TSN domain enhanced spliceosome
formation, particularly the formation of the complex A
4492 Nucleic Acids Research, 2007, Vol. 35, No. 13and the transition from A to B complex. In contrast, p100
fragment encompassing the SN domains of the p100
severely inhibited the in vitro spliceosome assembly, but
we do not know if it has any biological signiﬁcance.
Because p100 only accelerated the kinetics of the spliceo-
some assembly, but did not aﬀect the overall level of
splicing, we hypothesize that p100 may function by
recruiting snRNPs, particularly the U4/U6.U5
tri-snRNP, onto spliceosome as supported by the speciﬁc
interactions between snRNPs and p100.
An important question related to the function of p100
in spliceosome assembly in vivo is that why has p100
passed undetected in the extensive proteomic analyses
of spliceosomes (12–14) and why it can enhance
the splicing of a generic splicing substrate. A possible
explanation is that compared to the previously identiﬁed
factors functioning during spliceosome assembly, such
as SMN or SMNrp/SPF30, the p100 is a large modular
protein composed of multiple SN-domains in addition
to the TSN domain and has thus other functions besides
RNA processing. Our previous studies indicated distinct
functions for the diﬀerent domains, and the SN-like
domain alone was suﬃcient to enhance STAT6-mediated
transcription activity in response to IL-4 stimulation (21),
while expression of the TSN alone did not aﬀect
the transcriptional response. Here we show that
the isolated TSN stimulated the kinetics of spliceosome
assembly, while the isolated SN-domain was highly
inhibitory in the in vitro splicing assay. The stimulation
of splicing of a generic splicing substrate may reﬂect the
conditions of the in vitro reaction in which the p100
protein is free in the solution, while in vivo it may be
associated with speciﬁc genes via promoter regions. Taken
together, the results from this and previous studies suggest
that the human p100 protein is dual function regulator
of gene expression, capable of interacting with diﬀerent
protein complexes through distinct domains. Thus, it
is possible that p100 protein may cooperate with RNA
pol II and selectively coordinate gene transcription and
pre-mRNA splicing.
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